Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
35
Frequently Asked Questions
What is market cap of Ayala Pharmaceuticals Inc?
The market cap of Ayala Pharmaceuticals Inc is $7.46M
What is the 52 week high for Ayala Pharmaceuticals Inc?
The 52 week high for Ayala Pharmaceuticals Inc is $7.13.
What is the 52 week low for Ayala Pharmaceuticals Inc?
The 52 week low for Ayala Pharmaceuticals Inc is $0.3568.
What is Ayala Pharmaceuticals Inc stock price today?
Ayala Pharmaceuticals Inc' stock price today is $0.4758.
What is the pe ratio of Ayala Pharmaceuticals Inc?
The PE ratio of Ayala Pharmaceuticals Inc is -0.20.
What is the price to book ratio of Ayala Pharmaceuticals Inc?
The price to book ratio of Ayala Pharmaceuticals Inc is 0.8828.
What is Ayala Pharmaceuticals Inc's EBITDA?
Ayala Pharmaceuticals Inc's EBITDA is -37.393.
What is the 50-day moving average of Ayala Pharmaceuticals Inc?
The 50-day moving average of Ayala Pharmaceuticals Inc is 0.5277.
How many employess does Ayala Pharmaceuticals Inc has?